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ABSTRACT
BRCA1/BRCA2 mutations are the most common high-penetrant genes associated 
with increased lifetime risk for hereditary breast and ovarian cancer (HBOC). 
Although genetic testing is included in standard of care in Western developed 
countries, there are still variations of its availability and risk assessment for 
HBOC in Asia. The clinical strategies and cancer management varies by country 
across Asia. The Asian BRCA Consortium has gathered information from 14 
Asian countries to review genetic counselling/testing uptake rates and clinical 
management options in these countries. In addition, economic factors, healthcare 
and legal frameworks, and cultural issues affecting the genetic service availability 
in Asia were discussed. Mutation spectrum, VUS rates, and the increase use of 
NGS gene panel testing pose a decisional issue in the clinical management of 
Hereditary Breast cancer in Asia, these issues would be discussed here as well.
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